A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

ABSTRACT:

Background

In phase I studies, poziotinib has shown meaningful efficacy against various types of cancers. This phase 2 study aimed to investigate the efficacy and safety of poziotinib in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC).

Methods

Overall, 49 patients were enrolled (median age, 62 years; age range, 21-78 years). Patients received a median of two prior treatments including chemotherapy and others and received 12 mg poziotinib orally once daily as part of a 28-day cycle. The primary endpoint was objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Targeted capture sequencing was performed using available tissues to identify translational biomarkers related to clinic

SUBMITTER: Lee JH 

PROVIDER: S-EPMC8525103 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature